NIH Begins Clinical Trial of New Medication for Alcohol Use Disorder

alcohol - 83898022A clinical trial investigating a potential treatment for alcohol use disorder (AUD) was announced by the National Institute of Alcohol Abuse and Alcoholism (NIAAA).

The study will assess the safety and efficacy of gabapentin enacarbil (HORIZANT) in extended-release tablets for treating moderate to severe AUD. NIAAA is part of the National Institutes of Health.

Gabapentin is already widely prescribed to treat pain conditions and epilepsy.

HORIZANT contains gabapentin enacarbil, a prodrug of gabapentin that is converted to gabapentin in the body. A prodrug is an inactive form that is converted to an active form through metabolic processes. Gabapentin enacarbil is currently approved in the U.S. for the treatment of restless leg syndrome (RLS) and nerve pain caused by shingles. NIAAA is working in partnership with the biopharmaceutical company XenoPort Inc., of Santa Clara, California, which will supply gabapentin enacarbil for the study.

NIAAA will enroll 346 patients in a randomized, double blind, placebo-controlled clinical trial of gabapentin enacarbil in patients with AUD at 10 sites across the United States.

The study will assess the safety and efficacy of 1200 mg of gabapentin (administered in two daily doses of 600 mg), compared with placebo, to reduce drinking in patients who report four or more symptoms of AUD, as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

In a recent study supported by NIAAA, researchers at The Scripps Research Institute in La Jolla, California, found that alcohol dependent patients using gabapentin were more likely than those taking placebo to stop drinking or refrain from heavy drinking.

Scientists at XenoPort designed gabapentin enacarbil extended-release tablets to address certain limitations of drug levels in the body, which may make it a more attractive treatment option for people with AUD.

Alcohol use disorder affects about 16.6 million adults in the United States and has an estimated societal cost of $223.5 billion each year, primarily from lost productivity, but also from health care and property damage costs.

Currently, three medications are approved by the U.S. Food and Drug Administration for treating alcohol dependence: disulfram, an older drug that blocks the metabolism of alcohol and causes nausea; acamprosate, which helps support abstinence and can ease symptoms of withdrawal; and naltrexone, which can help people reduce heavy drinking.

For further information about the NIAAA clinical trial of gabapentin enacarbil for the treatment of AUD, click here.

To learn more about Alcohol and Alcoholism, please click here.



No comments made yet. Be the first to submit a comment
Monday, 17 June 2019

Thank you for visiting Facing Addiction with NCADD

For 24-hour free and confidential referrals and information about mental and/or substance use disorders, prevention, treatment, and recovery in English and Spanish, please call the SAMSHA national help line: 1-800-662-HELP (4357)


For referral information and other resources, please visit the Recovery Resource Hub